期刊文献+

血清S-CD105与VEGF联合监测复发转移性乳腺癌的意义

Clinical Significance of Serum S-CD105 and VEGF Levels of Patients with Postoperative Recurrent and Metastatic Breast Cancer
原文传递
导出
摘要 目的:探讨联合检测血清S-CD105和VEGF表达对乳腺癌术后复发、转移的临床意义。方法:用酶联免疫吸附实验(ELISA)分别检测50例复发转移性乳腺癌、20例原发性乳腺癌、20例乳腺良性疾病及15例健康女性血清S-CD105和VEGF的浓度;用微粒子化学发光法检测复发转移患者同期血清CEA、CA15-3的浓度。结果:复发转移性乳腺癌组血清S-CD105、VEGF浓度明显高于原发性乳腺癌组、乳腺良性疾病组及健康对照组(P〈0.05)。血清S—CD105与VEGF联合表达阳性率高于CEA与CA15-3联合表达率,差异有统计学意义(P〈0.05)。结论:复发转移性乳腺癌患者血清S-CD105与VEGF联合检测优于CEA与CA15-3联合检测,可能对乳腺癌患者术后复发转移的早期诊断有重要的临床价值。 Objective:To explore the levels and clinical significance of serum S-CDI05 and VEGF of patients with postoperative recurrent and metastatic breast cancer. Methods:Serum S-CD105 and VEGF of 50 postoperative patients with recurrent and metastatic breast cancer, 20 patients with primary breast cancer, 20 patients with breast benign disease, and 15 healthy controls were detected by ELISA. CEA, CA15-3 of the same patients were measured by microparticle chemilumin - escence immunoassay in corresponding period. Restilts:The serum S-CDI05 and VEGF levels of the patients with postoperative recurrent and metastatic breast cancer was much higher than primary breast cancer , breast benign disease and healthy controls (P 〈 0. 05 ). The positive rate of the combining test of serum S-CD105 and VEGF of patients with postoperative recurrent and metastatic breast cancer was higher than that of CEA and CA15-3 (P 〈 0.05 ). Conclusions :The positive rate of combining test of serum S-CD105 and VEGF is higher than that of CEA and CA15-3. It is expected to be markers for the early diagnosis of recurrence and metastasis of breast cancer.
出处 《解剖与临床》 2012年第4期325-327,共3页 Anatomy and Clinics
关键词 乳腺肿瘤 CD105 VEGF 复发 转移 血清 Breast neoplasm/cancer CD105 VEGF Recurrence Metastasis Serum
  • 相关文献

参考文献10

二级参考文献41

  • 1黄维清,于建宪.CD105的分子结构及其分布[J].齐鲁医学杂志,2005,20(3):225-228. 被引量:6
  • 2马力,范忠林,刘月平,王小玲.乳腺癌中CD105表达及相关因素分析[J].临床与实验病理学杂志,2005,21(5):548-550. 被引量:6
  • 3Cox G,Jones JL,Walker RA,et al.Angiogenesis and non-small celllung cancer[J].Lung cancer,2000,27(2):81-100.
  • 4Lee JK,Hong YJ,Han CJ,et al.Clinical usefuness of serum and plasma Vascular endothelial growth factor in cancer patients:which is the optimal specimen[J].Int J oncol,2000,17(1):149-152.
  • 5Tempfer C,Obermair A,Hefler L,et al.Vascular endothelial growth factor in the serum concentration in ovarian cancer[J].Obstet Gynecol,1998,92(1):360-363.
  • 6Rosenman J, Bernard S, Kober C, et al. Local recurrences in patients with breast cancer at the North Carolina Memorial Hospital (1970-1982). Cancer, 1986,57 : 1421-1425.
  • 7Duffy MJ. Serum Tumor Markers in Breast Cancer: Are they of Clinical Value? Clin Chem,2006,52:345-351.
  • 8蒋一宁主编.肿瘤核医学.第1版.北京:人民卫生出版社,2002.106-108.
  • 9Edgren M,Lennernas B,Lassn A, et al. Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas [J]. Anticancer Res,1999,19 (4): 869-- 873.
  • 10Kazunari S, Norihiko T, Ryusei S, et al. Increased serum levels of VEGF in patients with renal cell carcinoma [J]. Jpn J Cancer Res, 1999,90 (4) : 874-- 879.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部